Tolerability and side-effects of post-exposure prophylaxis for HIV infection

Lancet

Volumn 355, Issue 9205, 2000, Pages 722-723

  Parkin, J M ^a   Murphy, M ^a   Anderson, J ^a   El Gadi, S ^b   Forster, G ^a   Pinching, A J ^c,d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG TOLERABILITY; FATIGUE; GALACTORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; NEEDLESTICK INJURY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; URTICARIA; VOMITING;

EID: 0034716479     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)05005-9     Document Type: Article

References (5)

1. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 44:1995;929-933.
2. Guidelines on post-exposure prophylaxis for health care workers occupationally exposed to HIV. 1997;Department of Health, London.
3. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. MMWR Morb Mortal Wkly Rep. 47:1998;1-14.
4. Hammer S.M., Squires K.E., Hughes M.D.et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV and infections and CD4 cell counts of 200 per cu mm or less. N Engl J Med. 337:1997;725-733.
5. Yerly S., Kaiser L., Race E., Bru J.-P., Clavel F., Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 354:1999;729-733.